Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon Durrant

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
The New England Journal of Medicine|January 26, 2007
Posaconazole or fluconazole for prophylaxis in severe graft-versus-host diseaseAndrew J Ullmann, Jeffrey H Lipton, David H Vesole, et al.
Bone Marrow Transplantation|October 27, 2023
Quantifying skin cancer risk following allogeneic haematopoietic cell transplant in Queensland, AustraliaPhilip Wong, David C Whiteman, Catherine M Olsen, et al.
Bone Marrow Transplantation|August 15, 2022
High incidence of resistant breakthrough invasive fungal infections (IFD) in patients treated for acute gastrointestinal graft-versus-host disease (GI GVHD) following allogeneic haematopoietic cell transplantationYin Yuan, Philip Wong, Jason P Butler, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 31, 2016
VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple MyelomaDavid S Siegel, Meletios Dimopoulos, Sundar Jagannath, et al.
Stem Cells (Dayton, Ohio)|June 4, 2009
Human gastrointestinal neoplasia-associated myofibroblasts can develop from bone marrow-derived cells following allogeneic stem cell transplantationDaniel L Worthley, Andrew Ruszkiewicz, Ruth Davies, et al.
Leukemia & Lymphoma|May 22, 2014
An imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute leukemia: long-term results of the CMLALL1 trialJason D Lickliter, Kerry Taylor, Jeff Szer, et al.
The New England Journal of Medicine|January 29, 2015
Ruxolitinib versus standard therapy for the treatment of polycythemia veraAlessandro M Vannucchi, Jean Jacques Kiladjian, Martin Griesshammer, et al.
European Journal of Haematology|November 27, 2015
Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapyRuben Mesa, Srdan Verstovsek, Jean-Jacques Kiladjian, et al.
British Journal of Haematology|July 10, 2018
Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamideClaire N Harrison, Martin Griesshammer, Carole Miller, et al.
Blood|July 17, 2004
Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutationsSusan Branford, Zbigniew Rudzki, Ian Parkinson, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
The New England Journal of Medicine|January 26, 2007
Posaconazole or fluconazole for prophylaxis in severe graft-versus-host diseaseAndrew J Ullmann, Jeffrey H Lipton, David H Vesole, et al.
Bone Marrow Transplantation|October 27, 2023
Quantifying skin cancer risk following allogeneic haematopoietic cell transplant in Queensland, AustraliaPhilip Wong, David C Whiteman, Catherine M Olsen, et al.
Bone Marrow Transplantation|August 15, 2022
High incidence of resistant breakthrough invasive fungal infections (IFD) in patients treated for acute gastrointestinal graft-versus-host disease (GI GVHD) following allogeneic haematopoietic cell transplantationYin Yuan, Philip Wong, Jason P Butler, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 31, 2016
VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple MyelomaDavid S Siegel, Meletios Dimopoulos, Sundar Jagannath, et al.
Stem Cells (Dayton, Ohio)|June 4, 2009
Human gastrointestinal neoplasia-associated myofibroblasts can develop from bone marrow-derived cells following allogeneic stem cell transplantationDaniel L Worthley, Andrew Ruszkiewicz, Ruth Davies, et al.
Leukemia & Lymphoma|May 22, 2014
An imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute leukemia: long-term results of the CMLALL1 trialJason D Lickliter, Kerry Taylor, Jeff Szer, et al.
The New England Journal of Medicine|January 29, 2015
Ruxolitinib versus standard therapy for the treatment of polycythemia veraAlessandro M Vannucchi, Jean Jacques Kiladjian, Martin Griesshammer, et al.
European Journal of Haematology|November 27, 2015
Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapyRuben Mesa, Srdan Verstovsek, Jean-Jacques Kiladjian, et al.
British Journal of Haematology|July 10, 2018
Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamideClaire N Harrison, Martin Griesshammer, Carole Miller, et al.
Blood|July 17, 2004
Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutationsSusan Branford, Zbigniew Rudzki, Ian Parkinson, et al.
Pageof 6